Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice

Neurobiology of Disease

Volumn 14, Issue 1, 2003, Pages 10-18

  Lemere, Cynthia A ^a,f   Spooner, Edward T ^a   LaFrancois, John ^b   Malester, Brian ^b   Mori, Chica ^a   Leverone, Jodi F ^a   Matsuoka, Yasuji ^b,c   Taylor, Jennie W ^d   DeMattos, Ronald B ^d   Holtzman, David M ^d   Clements, John D ^e   Selkoe, Dennis J ^a   Duff, Karen E ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-15]; BRAIN PROTEIN; EPITOPE; ESCHERICHIA COLI ENTEROTOXIN; FREUND ADJUVANT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOLOGICAL ADJUVANT; PROTEIN ANTIBODY; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; BRAIN LEVEL; CENTRAL NERVOUS SYSTEM; CLEARANCE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DYSTROPHY; ESCHERICHIA COLI; FACE; FEMALE; GLIOSIS; HISTOPATHOLOGY; IMMUNIZATION; KIDNEY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; SENILE PLAQUE; SPLEEN; TRANSGENIC MOUSE; TREATMENT OUTCOME;

EID: 0041332884     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-9961(03)00044-5     Document Type: Article

References (23)

1. Backsai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P., Schenk D., Hyman B.T. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7:2001;369-372.
2. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:2000;916-919.
3. Brayden D., Templeton L., McClean S., Barbour R., Huang J., Nguyen M., Ahern D., Motter R., Johnson-Wood K., Vasquez N., Schenk D., Seubert P. Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered β-amyloid in mice. Vaccine. 19:2001;4185-4193.
4. DeMattos R.B., Bales K.R., Cummins D., Dodart J.-C., Paul S.M., Holtzman D.M. Peripheral anti-Aβ antibody alters CND and plasma clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 98:2001;8850-8855.
5. DeMattos R.B., Bales K.R., Cummins D.J., Paul S.M., Holtzman D.M. Brain to plasma amyloid-β efflux a measure of brain amyloid burden in a mouse model of Alzheimer's disease . Science. 295:2002;2264-2267.
6. Dodart J.-C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., Paul S.M. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci. 5:2002;452-457.
7. Duff K., Eckman C., Zehr C., Yu X., Prada C.-M., Perez-Tur J., Hutton M., Buee L., Harigaya Y., Yager D., Morgan D., Gordon M.N., Holcomb L., Refolo L., Zenk B., Hardy J., Younkin S. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature. 383:1996;710-713.
8. Frenkel D., Katz O., Solomon B. Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration. Proc. Natl. Acad. Sci. USA. 97:2000;11455-11459.
9. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C.M., Eckman C., Younkin S., Hsiao K., Duff K. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4:1998;97-100.
10. Hsiao K., Chapman P., Nilsen S., Ekman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
11. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St. George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:2000;979-982.
12. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D., Lieberburg I., Schenk D., Seubert P., MConlogue L. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 94:1997;1550-1555.
13. Lemere C.A., Blustzjan J.K., Yamaguchi H., Wisniewski T., Saido T.C., Selkoe D.J. Sequence of deposition of heterogeneous amyloid β-peptides and Apo E in Down syndrome implications for initial events in amyloid plaque formation . Neurobiol. Dis. 3:1996;16-32.
14. Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., Desai R., Hancock W.W., Weiner H.L., Selkoe D.J. Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. N.Y. Acad. Sci. 920:2000;328-331.
15. Lemere C.A., Spooner E.T., Leverone J.F., Mori C., Clements J.D. Intranasal immunotherapy for the treatment of Alzheimer's disease effects of mucosal adjuvant, Escherichia coli heat-labile enterotoxin, LT . Neurobiol. Aging. 23:2002;991-1000.
16. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
17. Mucke M., Masliah E., Yu G.-Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L. High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice synaptotoxicity without plaque formation . J. Neurosci. 20:2000;4050-4058.
18. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vendevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
19. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399:(Suppl.):1999;A23-A31.
20. Sigurdsson E.M., Scholtzova H., Mehta P.D., Frangione B., Wisniewski T. Immunization with a non-toxic/non-fibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 159:2001;439-447.
21. Solomon B., Koppel R., Hanan E., Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc. Natl. Acad. Sci. USA. 93:1996;452-455.
22. Solomon B., Koppel R., Frenkel D., Hanan-Aharon E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA. 94:1997;4109-4112.
23. Weiner H.L., Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., Issazadeh S., Hancock W.W., Selkoe D.J. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48:2000;567-579.